(B) in paragraph (7), by striking ‘‘and 
comparisons of transplant centers regarding 
search and other costs that prior to transplan-
tation are charged to patients by transplant 
centers; and’’; 
(C) in paragraph (8), by inserting ‘‘and 
outreach’’ after ‘‘and demonstration’’; 
(D) at the end of paragraph (8), by strik-
ing the period and inserting a semicolon; 
(E) 
by 
redesignating 
paragraphs 
(3) 
through (8) as paragraphs (4) through (9); 
(F) by inserting after paragraph (2), the 
following: 
‘‘(3) maintain and expand medical emergency 
contingency response capabilities in concert with 
Federal programs for response to threats of use of 
terrorist or military weapons that can damage mar-
row, such as ionizing radiation or chemical agents 
containing mustard, so that the capability of sup-
porting patients with marrow damage from disease 
can be used to support casualties with marrow dam-
age;’’; and 
(G) by adding at the end the following: 
‘‘(10) conduct and support research to improve 
the availability, efficiency, safety, and cost of trans-
plants from unrelated donors and the effectiveness 
of Registry operations; 
‘‘(11) increase the number of umbilical cord 
blood units listed in the Registry and assist cord 
blood banks in the Registry program in accordance 
with subsection (c); and 
‘‘(12) establish bylaws and procedures—
‘‘(A) to prohibit any member of the board 
of directors of the Registry who has an employ-
ment, governance, or financial affiliation with a 
donor center, recruitment group, transplant 
center, or cord blood bank from participating in 
any decision that materially affects the center, 
recruitment group, or cord blood bank; and 
‘‘(B) to limit the number of members of 
the board with any such affiliation.’’; 
(3) in subsection (c)—
(A) in clause (ii) of paragraph (2)(A), by 
striking ‘‘, including providing updates’’; and 
(B) in paragraph (3), by striking ‘‘the 
availability, as a potential treatment option, of 
receiving a transplant of bone marrow from an 
unrelated donor’’ and inserting ‘‘transplants 
from unrelated donors as a treatment option
and resources for identifying and evaluating 
other therapeutic alternatives’’; 
(4) in subsection (d)—
(A) in paragraph (2)(C), by inserting ‘‘and 
assist with information regarding third party 
payor matters’’ after ‘‘ongoing search for a 
donor’’; 
(B) in paragraph (2)(F)—
(i) by redesignating clause (v) as 
clause (vi); and 
(ii) by inserting after clause (iv) the 
following: 
‘‘(v) Information concerning issues 
that patients may face after a transplant 
regarding continuity of care and quality of 
life.’’; and 
(C) in paragraph (3)(B), by striking ‘‘Of-
fice may’’ and inserting ‘‘Office shall’’; 
(5) in subsection (g), by striking ‘‘the bone 
marrow donor program of the Department of the 
Navy’’ and inserting ‘‘Department of Defense Mar-
row Donor Recruitment and Research Program op-
erated by the Department of Navy’’; 
(6) in subsection (h)—
(A) by striking ‘‘APPLICATION.—’’ and in-
serting ‘‘CONTRACTS.—’’; 
(B) by striking ‘‘To be eligible’’ and insert-
ing the following: ‘‘(1) APPLICATION.—To be 
eligible’’; and 
(C) by adding at the end the following: 
‘‘(2) CONSIDERATIONS.—In awarding contracts 
under this section, the Secretary shall give substan-
tial weight to the continued safety of donors and pa-
tients and other factors deemed appropriate by the 
Secretary.’’; 
(7) in subsection (i), by striking ‘‘include’’ and 
inserting ‘‘be’’; and 
(8) by striking subsection (l). 
(b) BONE MARROW SCIENTIFIC REGISTRY.—Section 
379A of the Public Health Service Act (42 U.S.C. 274l) 
is amended—
(1) in subsection (a), by adding at the end the 
following: ‘‘The scientific registry shall participate in 
medical research that has the potential to improve 
transplant outcomes.’’; 
(2) in subsection (c), by striking ‘‘Each such re-
port shall in addition include the data required in 
section 379(l) (relating to pretransplant costs)’’; and 
(3) adding after subsection (c):
‘‘(d) PUBLICLY AVAILABLE DATA.—The scientific 
registry shall make relevant scientific information not con-
taining personal identifiers available to the public in the 
form of summaries and data sets to encourage medical re-
search and to provide information to transplant programs, 
physicians, and patients.’’
(c) BONE MARROW AND MARROW DEFINED.—Part 
I of title III of the Public Health Service Act (42 U.S.C. 
274k et seq.) is amended—
(1) by redesignating section 379B as section 
379C; and 
(2) by inserting after section 379A the fol-
lowing: 
‘‘SEC. 379B. BONE MARROW AND MARROW DEFINED. 
‘‘For purposes of this part, the terms ‘bone marrow’ 
and ‘marrow’ include bone marrow and any other source 
of hematopoietic progenitor cells the acquisition or use of 
which is not inconsistent with Federal law.’’. 
(d) AUTHORIZATION OF APPROPRIATIONS.—Section 
379C of the Public Health Service Act, as redesignated 
by subsection (c), is amended to read as follows: 
‘‘SEC. 379C. AUTHORIZATION OF APPROPRIATIONS. 
‘‘(a) IN GENERAL.—For the purpose of carrying out 
this part, there are authorized to be appropriated 
$32,000,000 for fiscal year 2004, and such sums as may
be necessary for each of the fiscal years 2005 through 
2008. 
‘‘(b) EMERGENCY CONTINGENCY RESPONSE CAPA-
BILITIES.—In addition to any amounts authorized to be 
appropriated under subsection (a), there are authorized to 
be appropriated such sums as may be necessary for the 
maintenance and expansion of emergency contingency re-
sponse capabilities under section 379(b)(3).’’.
Æ